Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Criteria for inclusion were positivity for T cruzi as confirmed by 2 or more serological tests (indirect immunofluorescence, ELISA, and/or indirect hemagglutination) and having cardiomyopathy.~* Cardiomyopathy was present when at least 3 of the following criteria were fulfilled:~  * LV enddiastolic diameter (LVDD) N55 mm~ * LVDD/body surface area \> 2.7cm/m2~ * LV ejection fraction (LVEF) \< 55%~ * QRS interval \> 120 ms~ * echocardiographic evidence of diffuse or segmental systolic wall motion abnormalities.~Exclusion Criteria:~* Exclusion criteria were being pregnant~* Using any h-blocker~* Having additional comorbidities (eg, hypertension, diabetes mellitus, thyroid dysfunction, chronic obstructive pulmonary disease, asthma, and renal or hepatic failure).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RASi plus placebo (Type: PLACEBO_COMPARATOR): RAS inhibition was optimized and after patients were randomly assigned to receive placebo
- RASi plus carvedilol (Type: EXPERIMENTAL): RAS inhibition was optimized and after patients were randomly assigned to receive carvedilol

Based on this trial design, predict the completion outcome and termination type (if applicable).